Interval debulking surgery for advanced epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Tangjitgamol, Siriwan ^a   Manusirivithaya, Sumonmal ^a   Laopaiboon, Malinee ^b   Lumbiganon, Pisake ^c   Bryant, Andrew ^d  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COCHRANE LIBRARY; CYTOREDUCTIVE SURGERY; HUMAN; MEDLINE; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; DRUG EFFECTS; FEMALE; INDUCTION CHEMOTHERAPY; META ANALYSIS; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; SURVIVAL RATE; TUMOR VOLUME;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TUMOR BURDEN;

EID: 84966350077     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006014.pub7     Document Type: Review

References (68)

1. Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology 1994;101:142-6.
2. Varma R, Blackledge G, Redman C, Luesley D, Chan KK, Mould J. A randomised trial of intervention debulking surgery and the duration of cis-platinum combination chemotherapy in advanced epithelial ovarian cancer (EOC). Annals of Oncology. 1990; Vol. 1 (Suppl 9):4.
3. Rose PG, Nerenston S, Brady MF, Clarke Pearson D, Olt G, Rubin SC, et al. Operative morbidity following primary and interval debulking surgery for advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 23:450.
4. Rose PG, Nerenstone S, Brady M, Clarke Pearson D, Olt G, Rubin SC, et al. A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proceedings of the American Society of Clinical Oncology. 2002; Vol. 21 (Pt 1):201a.
5. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. The New England Journal of Medicine 2004;351:2489-97.
6. Van der Burg ME, Coens C, Van Lent M, Kobierska A, Colombo N, Favalli G, et al. After ten years follow-up interval debulking surgery remains a significant prognostic factor for survival and progression free survival for advanced ovarian cancer: the EORTC Gynaecological Cancer Group study. International Journal of Gynecological Cancer. 2004; Vol. 14 (Suppl 1):3.
7. Van der Burg ME, Van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Intervention debulking surgery (IDS) does improve survival in advanced epithelial ovarian cancer (EOC); an EORTC gynecological cancer cooperative group (GCCG) study. Proceedings of the American Society of Clinical Oncology. 1993; Vol. 12:258.
8. Van der Burg ME, Van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC) - an EORTC Gynecological Cancer Cooperative Group (GCCG) study. European Journal of Cancer. 1993; Vol. 29 (Suppl 6):S132.
9. Van der Burg MEL, Coens C, Van Lent M, Kobierska A, Colombo M, Favalli G, et al. The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; the EORTC GCG 55865 study. International Journal of Gynecologic Cancer. 2005; Vol. 15 (supplement 2):79.
10. Van der Burg MEL, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the EORTC. The New England Journal of Medicine 1995;332(10):629-34.
11. Van der Burg MEL, Van Lent M, Buyse M, Kobierska A, Maggioni A, Favalli G, et al. The role of intervention debulking surgery in advanced epithelial ovarian cancer: An EORTC Gynecological Cancer Cooperative Group study. International Journal of Gynecological Cancer 1996;6 (5 Suppl 1):30-8.
12. Van der Burg MEL, Van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Secondary tumor debulking itself does not increase survival in advanced epithelial ovarian cancer (EOC); an EORTC Gynecological Cancer Cooperative (GCCG) study. International Journal of Gynecological Cancer. 1993; Vol. 3 (Suppl 1):52.
13. Van der Burg MEL, Van Lent M, Kobierska A, Pitelli MR, Favalli G, Lacave AJ, et al. After 6 years follow-up intervention debulking surgery remains an independent prognostic factor for survival in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. International Journal of Gynecological Cancer. 1997; Vol. 7 (Suppl 2):28.
14. Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecologic Oncology 2006;100:455-61.
15. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecologic Oncology 2003;88:9-16.
16. Dutta T, Sharma H, Kumar L, Dinda AK, Kumar S, Bhatla N, et al. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis. Cancer Chemotherapy and Pharmacology 2005;56(4):427-35.
17. Evdokimova NI, Grigorova TM. Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer. Voprosy onkologii 1982;28(7):28-34.
18. Fuso L, Amant F, Neven P, Berteloot P, Vergote I. Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: A single institution phase II study in 24 patients. International Journal of Gynecological Cancer 2006;16 (Suppl 1):60-7.
19. Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. European Journal Gynaecologic Oncology 2006;27:25-8.
20. Ikeba K, Okubo M, Takeda S, Kinoshita K, Maeda H. Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer. International Journal Clinical Oncology 2004;9:113-9.
21. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis. Cancer 2001;92:2585-91.
22. Janga D, Kumar L, Kumar S, Shukla NK, Thulkar S, Singh R. Neoadjuvant chemotherapy (CT) followed by debulking surgery vs upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma (EOC): a prospective, randomized study. Proceedings of the American Society of Clinical Oncology 2003. 2007; Vol. 22:487:Abstract 1957.
23. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Vijayaraghavan M, et al. Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study - interim results. Proceeding of the ASCO Annual Meeting 2007, Part I. 2007; Vol. 28, issue 18 (Suppl):Abstract 5531.
24. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Shukla NK. Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (eoc): A prospective, randomized study. Indian Journal of Medical and Paediatric Oncology 2009;30(1):15. [NCT00715286]
25. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. Journal of Obstetric and Gynaecological Research 2006;32:99-106.
26. Liu EL, Mi RR. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Chinese Medical Journal 2004;117:1547-51.
27. Madhuri TK, Ashbourne W, Butler-Manuel SA, Tailor A. RCT to evaluate utility and efficacy of neutral argon plasma as new technology in achieving complete cytoreduction of advanced epithelial ovarian carcinoma-initial feasibility study. 15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia. 2014; Vol. 245.
28. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, et al. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecologic Oncology 2009;112(2):394-399.
29. Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecologic Oncology 2009;113(1):57-62.
30. Onda T, Yoshikawa H, Shibat a T, Nakamura K, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602. Journal of Clinical Oncology. 2014; Vol. 32:suppl; abstr 5508.
31. Park-Simon T, Jänicke F, Ortmann O, Hilfrich J, Breitbach G, Höss C, et al. A randomized multicenter phase II study on neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian carcinomas (PRIMOVAR). Journal of Clinical Oncology: 2006 ASCO Annual meeting proceedings 2006;24(18S (June 20 Supplement)):Abstract 15025.
32. Polcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR). Oncology Reports 2009;22(3):605-613.
33. Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. European Journal of Gynaecologic Oncology 2001;22:287-91.
34. Solomon J. The role of surgical reexploration following chemotherapy in ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology 1988;28:121-6.
35. Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR III, Markman M, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelail ovarian, fallopian tube or primary peritoneal cancer: Soutwest Oncology Group Study S0009. Gynecologic Oncology 2009;112:444-9.
36. EORTC 55971. A randomized phase III study comparing upfront debulking surgery vs neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. IGCS 12th Biennial Meeting. 2008.
37. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 2010;363(10):943-53.
38. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001;91:2329-34.
39. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20:1248-59.
40. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology 2006;103(3):1070-6.
41. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecologic Oncology 2007;104(2):480-90.
42. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
43. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
44. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). BMJ Publication Group, London, 2001.
45. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
46. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD007565.pub2]
47. Elit A, Carey M. The role of interval debulking surgery in advanced ovarian cancer: a meta-analysis. International Journal of Gynecological Cancer. 1995; Vol. 5 (Suppl 1):37 (abstract).
48. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Vito Zakut H, Mancuso S, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 2003;65:316-22.
49. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Journal of the National Cancer Institute Monographs 1975;42:101-4.
50. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
51. Hoskins WJ, McGuire WP, Brady MF, Homsley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1994;170:974-80.
52. Jacob JH, Gerhenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecologic Oncology 1991;42:146-50.
53. Kayikçioglu F, Köse MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced ovarian carcinoma. International Journal of Gynecological Cancer 2001;11(6):446-70.
54. Kehoe S, Shafi M, Luesley D, Neijt JP, Cannistra SA, Van der Burg MEL, et al. Interval cytoreduction in ovarian cancer. New England Journal of Medicine 1995;333:254-5.
55. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics and Gynecology 1989;73:61-5.
56. Loizzi V, Cormio G, Resta L, Rossi CA, Di Gilio AR, Cuccovillo A, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. International Journal of Gynecological Cancer 2005;15:217-23. [MEDLINE: 15823102]
57. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecologic Oncology 2003;90:163-9.
58. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Journal of the American College of Surgeons 2003;197:955-63.
59. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD005343.pub3]
60. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
61. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer:long term survival. Gynecologic Oncology 1999;72:93-9.
62. Shibata K, Kikkawa F, Mika M, Suzuki Y, Kajiyama H, Ino K, et al. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors. International Journal of Gynecological Cancer 2003;13:587-92.
63. Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. International Journal of Gynecological Cancer 1996;6:356-61.
64. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA: a Cancer Journal for Clinicians 2015;65(2):87-108.
65. Van der Burg ME, Vergote I, Gynecological Cancer Group of the EORTC. The role of interval debulking surgery in ovarian cancer. Current Oncology Reports 2003;5:473-81.
66. Van der Burg MEL, Coens C, Van Lent M, Kobierska A, Colombo M, Favalli G, et al. The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; the EORTC GCG 55865 study. International Journal of Gynecologic Cancer. 2005; Vol. 15 (supplement 2):79.
67. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology 1998;71:431-6.
68. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2005;23:5605-12.